Economic impact of introducing TYRX amongst patients with heart failure and reduced ejection fraction undergoing implanted cardiac device procedures: a retrospective model based cost analysis

References

• Uslan DZ, Tleyjeh IM, Baddour LM, et al. Temporal trends in permanent pacemaker implantation: a population-based study. Am Heart J. 2008;155:896–903.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009;361:1329–1338.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.
   PubMed Web of Science ®Google Scholar
• Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–2158.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–1549.
   PubMed Web of Science ®Google Scholar
• Kurtz SM, Ochoa JA, Lau E, et al. Implantation trends and patient profiles for pacemakers and implantable cardioverter defibrillators in the United States: 1993-2006. Pacing Clin Electrophysiol. 2010;33:705–711.
   PubMed Web of Science ®Google Scholar
• Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007;116:1349–1355.
   PubMed Web of Science ®Google Scholar
• Uslan DZ, Baddour LM. Cardiac device infections: getting to the heart of the matter. Curr Opin Infect Dis. 2006;19:345–348.
   PubMed Web of Science ®Google Scholar
• Kolek MJ, Dresen WF, Wells QS, et al. Use of an antibacterial envelope is associated with reduced cardiac implantable electronic device infections in high-risk patients. Pacing Clin Electrophysiol. 2013;36:354–361.
   PubMed Web of Science ®Google Scholar
• Ahsan SY, Saberwal B, Lambiase PD, et al. A simple infection-control protocol to reduce serious cardiac device infections. Europace. 2014;16:1482–1489.
   PubMed Web of Science ®Google Scholar
• Da Costa A, Kirkorian G, Cucherat M, et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. Circulation. 1998;97:1796–1801.
   PubMed Web of Science ®Google Scholar
• Sandoe JA, Barlow G, Chambers JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British Heart Rhythm Society (BHRS), British Cardiovascular Society (BCS), British Heart Valve Society (BHVS) and British Society for Echocardiography (BSE). J Antimicrob Chemother. 2015;70:325–359.
   PubMed Web of Science ®Google Scholar
• de Oliveira JC, Martinelli M, Nishioka SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:29–34.
   PubMed Web of Science ®Google Scholar
• Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart. 2009;95:715–720.
   PubMed Web of Science ®Google Scholar
• Bloom H, Heeke B, Leon A, et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol. 2006;29:142–145.
   PubMed Web of Science ®Google Scholar
• Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace. 2015;17:767–777.
   PubMed Web of Science ®Google Scholar
• Gould J, Klis M, Porter B, et al. Predictors of mortality and outcomes in transvenous lead extraction for systemic and local infection cohorts. Pacing Clin Electrophysiol. 2019;42:73–84.
   PubMed Web of Science ®Google Scholar
• Sohail MR, Henrikson CA, Braid-Forbes MJ, et al. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med. 2011;171:1821–1828.
   PubMedGoogle Scholar
• Greenspon AJ, Patel JD, Lau E, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 2011;58:1001–1006.
   PubMed Web of Science ®Google Scholar
• Kay G, Eby EL, Brown B, et al. Cost-effectiveness of TYRX absorbable antibacterial envelope for prevention of cardiovascular implantable electronic device infection. J Med Econ. 2018;21:294–300.
   PubMed Web of Science ®Google Scholar
• Bloom HL, Constantin L, Dan D, et al. Implantation success and infection in cardiovascular implantable electronic device procedures utilizing an antibacterial envelope. Pacing Clin Electrophysiol. 2011;34:133–142.
   PubMed Web of Science ®Google Scholar
• Shariff N, Eby E, Adelstein E, et al. Health and economic outcomes associated with use of an antimicrobial envelope as a standard of care for cardiac implantable electronic device implantation. J Cardiovasc Electrophysiol. 2015;26:783–789.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. World-wide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT) 2015. Available from: https://clinicaltrials.gov/ct2/show/NCT02277990.
   Google Scholar
• Escobar C, Divison JA. [New recommendations of 2016 European Guidelines for the diagnosis and treatment of heart failure]. Semergen. 2017;43:328–329.
   PubMedGoogle Scholar
• Bongiorni MG, Kennergren C, Butter C, et al. The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction Outcomes. Eur Heart J. 2017;38:2995–3005.
   PubMed Web of Science ®Google Scholar
• Koerber SM, Turagam MK, Winterfield J, et al. Use of antibiotic envelopes to prevent cardiac implantable electronic device infections: a meta-analysis. J Cardiovasc Electrophysiol. 2018;29:609–615.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Briggs A, O’Hagan A, et al. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20:897–916.
   PubMed Web of Science ®Google Scholar
• Clementy N. Cardiovascular implantable electronic device infection: time to discuss reimbursement-Authors’ reply. Europace. 2018;20:2046.
   PubMed Web of Science ®Google Scholar
• NICOR. National Audit of Cardiac Rhythm Management Devices 2015-2016. London (UK): National Institute of Cardiovascular Outcomes Research; 2016.
   Google Scholar